Clinical Trials
23 trialsNCT06930755 2026-05-28
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Nerviano Medical Sciences
Phase 1 Recruiting
NCT06840886 2026-05-14
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
Phase 1 Recruiting
NCT02354547 2026-05-08
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
SynerGene Therapeutics, Inc.
Phase 1 Suspended
NCT04106219 2026-04-21
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05990738 2026-03-31
DAREONâ„¢-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT05429502 2025-10-10
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
Phase 1 Terminated
NCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
NCT05246111 2024-11-22
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT00881166 2024-08-02
SGI-0470-02
Astex Pharmaceuticals, Inc.
Phase 1 Completed
NCT03600649 2023-11-21
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Salarius Pharmaceuticals, LLC
Phase 1 Unknown
NCT04022876 2022-10-10
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
Aileron Therapeutics, Inc.
Phase 1 Terminated
NCT03987685 2022-02-16
Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
Athenex, Inc.
Phase 1 Completed
NCT03763123 2018-12-04
A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT00361803 2017-11-17
Topotecan Pharmacokinetic Characterization Study
GlaxoSmithKline
Phase 1 Completed
NCT00158886 2017-11-14
Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer
GlaxoSmithKline
Phase 1 Terminated
NCT00259935 2017-11-14
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00483860 2017-11-13
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
GlaxoSmithKline
Phase 1 Completed
NCT00732420 2017-11-13
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00046111 2017-05-30
A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00422682 2016-06-10
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT00770536 2015-09-29
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Amgen
Phase 1 Completed
NCT00682279 2015-04-17
A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Withdrawn
NCT00516438 2010-12-08
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
AstraZeneca
Phase 1 Completed